NextCure, Inc. (NXTC)

NextCure, Inc. (NXTC) Healthcare & Pipeline Overview

NextCure, Inc. is a clinical-stage biopharmaceutical firm pioneering immunomedicines for cancer and immune disorders. Their lead candidate, NC318, targets advanced solid tumors, while other pipeline assets like NC410 and NC762 are in earlier development. The company leverages a license agreement with Yale University for research and development.

What Is the Investment Thesis for NXTC?

NextCure, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value hinges on the successful development and commercialization of its pipeline of immunomedicines, particularly NC318, currently in Phase II trials. Positive clinical data from these trials would serve as a major catalyst, potentially leading to significant stock appreciation. However, the company's market capitalization of approximately $0.03 billion reflects the inherent risks associated with clinical-stage biopharmaceutical companies, including the possibility of clinical trial failures and regulatory hurdles. The company's beta of 1.58 indicates higher volatility compared to the broader market. Key value drivers include successful advancement of NC318 through clinical trials, strategic partnerships, and potential acquisition by a larger pharmaceutical company. The absence of a dividend reflects the company's focus on reinvesting capital into research and development.

Based on FMP financials and quantitative analysis

NXTC Key Highlights

• NextCure's lead product candidate, NC318, is in Phase II clinical trials for advanced or metastatic solid tumors, representing a key potential value driver.
• The company is developing NC410, currently in Phase I, targeting immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1).
• NextCure's pipeline includes NC762, an immunomedicine targeting human B7 homolog 4 protein (B7-H4), expanding its therapeutic focus.
• NC525, a novel LAIR-1 antibody, is in preclinical development targeting acute myeloid leukemia, blast cells, and leukemic stem cells.
• The company has a license agreement with Yale University, providing access to research and development capabilities.

Who Are NXTC's Competitors?

NXTC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NXTC's Key Strengths?

• Novel immunomedicine pipeline targeting unmet medical needs.
• Lead product candidate, NC318, in Phase II clinical trials.
• Strategic collaboration with Yale University.
• Experienced management team.

What Are NXTC's Weaknesses?

• Clinical-stage company with no currently approved products.
• Reliance on successful clinical trial outcomes.
• Limited financial resources.
• High cash burn rate.

What Could Drive NXTC Stock Higher?

• Data readout from Phase II clinical trials of NC318 for advanced solid tumors.
• Initiation of Phase II trials for NC410 in selected indications.
• Progression of NC762 through preclinical development.
• Announcement of new strategic partnerships or licensing agreements.

What Are the Key Risks for NXTC?

• Financial-distress signal — its Altman Z-Score of -20.13 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of NC318 or other pipeline candidates in clinical trials.
• Delays in regulatory approvals.
• Competition from other biotechnology and pharmaceutical companies.
• Dependence on securing additional funding to support research and development.

What Are the Growth Opportunities for NXTC?

• NC318 Clinical Advancement: The successful completion of Phase II clinical trials for NC318 and subsequent advancement to Phase III trials represent a significant growth opportunity. Positive data could lead to accelerated regulatory approval and market entry, addressing the unmet need for effective treatments for advanced solid tumors. The market for solid tumor therapies is estimated to be worth billions of dollars, offering substantial revenue potential for NextCure.
• NC410 Development: The progression of NC410 through Phase I clinical trials and into later-stage development presents another key growth opportunity. Blocking immune suppression mediated by LAIR-1 could have broad applications in treating various cancers and immune-related diseases. Successful development of NC410 could expand NextCure's pipeline and diversify its revenue streams.
• NC762 Expansion: The continued development of NC762, targeting B7-H4, offers a distinct growth avenue. B7-H4 is overexpressed in several cancers, making it a promising therapeutic target. Positive preclinical and clinical data could lead to strategic partnerships and further investment in this program, enhancing NextCure's market position.
• NC525 Preclinical Advancement: Advancing NC525 from preclinical development into clinical trials represents a longer-term growth opportunity. Targeting acute myeloid leukemia (AML) with a novel LAIR-1 antibody could address a significant unmet need in hematologic malignancies. Successful preclinical studies and initial clinical data would be crucial for attracting investment and advancing this program.
• Strategic Partnerships and Licensing: Forming strategic partnerships with larger pharmaceutical companies for the development and commercialization of NextCure's pipeline assets offers a significant growth opportunity. Licensing agreements could provide upfront payments, milestone payments, and royalties, bolstering NextCure's financial position and accelerating the development of its immunomedicines.

What Opportunities Does NXTC Have?

• Positive clinical trial data for NC318 and other pipeline candidates.
• Strategic partnerships with larger pharmaceutical companies.
• Expansion of pipeline through internal research and development.
• Potential for breakthrough therapy designations and accelerated regulatory approvals.

What Threats Does NXTC Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other biotechnology and pharmaceutical companies.
• Patent challenges and intellectual property disputes.

What Are NXTC's Competitive Advantages?

• Proprietary immunomedicine technology and intellectual property.
• Clinical trial data demonstrating the efficacy and safety of its drug candidates.
• Strategic partnerships with leading research institutions like Yale University.
• Experienced management team with expertise in drug development and commercialization.

What Does NXTC Do?

NextCure, Inc., founded in 2015 and headquartered in Beltsville, Maryland, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative immunomedicines. The company's core mission revolves around restoring normal immune function to combat cancer and other immune-related diseases. NextCure's lead product candidate, NC318, is currently undergoing Phase II clinical trials for the treatment of advanced or metastatic solid tumors. This represents a significant step in the company's efforts to address unmet medical needs in oncology. Beyond NC318, NextCure has a pipeline of other promising immunomedicines in various stages of development. NC410, for instance, is in Phase I clinical trials and is designed to block immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). NC762 is another immunomedicine targeting human B7 homolog 4 protein (B7-H4), while NC525, a novel LAIR-1 antibody, is in preclinical development targeting acute myeloid leukemia, blast cells, and leukemic stem cells. These programs reflect NextCure's commitment to exploring multiple avenues for harnessing the power of the immune system to fight disease. NextCure also has discovery and research programs focused on identifying other potential novel immunomodulatory molecules, demonstrating a long-term commitment to innovation in the field. The company's collaboration with Yale University through a license agreement further strengthens its research capabilities and access to cutting-edge science.

What Products and Services Does NXTC Offer?

• Discovers and develops novel immunomedicines.
• Focuses on restoring normal immune function to treat cancer.
• Develops therapies for other immune-related diseases.
• Conducts Phase II clinical trials for NC318, its lead product candidate, targeting advanced or metastatic solid tumors.
• Develops NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1.
• Develops NC762, an immunomedicine targeting human B7 homolog 4 protein (B7-H4).
• Advances NC525, a novel LAIR-1 antibody, in preclinical trials for acute myeloid leukemia.

How Does NXTC Make Money?

• Develops and patents novel immunomedicines.
• Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from agencies like the FDA.
• Potentially commercializes approved drugs directly or through partnerships.
• Generates revenue through product sales, licensing agreements, and milestone payments.

What Industry Does NXTC Operate In?

NextCure operates within the biotechnology industry, a sector characterized by high growth potential and substantial risk. The market for immunotherapies is expanding rapidly, driven by advances in understanding the immune system's role in fighting cancer and other diseases. Competition is intense, with numerous companies developing novel immunomedicines. NextCure's focus on LAIR-1 and B7-H4 targets differentiates it from some competitors. The biotechnology industry is subject to stringent regulatory oversight and requires significant investment in research and development. Success depends on clinical trial outcomes, regulatory approvals, and commercialization strategies.

Who Are NXTC's Key Customers?

• Patients with cancer and other immune-related diseases.
• Healthcare providers who prescribe and administer NextCure's therapies.
• Hospitals and clinics that utilize NextCure's products.
• Pharmaceutical companies that may partner with NextCure for development and commercialization.

FY2026 estForward Outlook

Wall Street analysts project NextCure, Inc. revenue of about $3.3M for fiscal 2026, with EPS near $-7.32. The estimate reflects 3 contributing analysts.

F-Score 1/9Financial Health

NextCure, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.13 places it in the distress zone, a signal of elevated financial risk.

NXTC Valuation & Market Position

With a $5.13M market cap, NextCure, Inc. sits in the micro-cap segment of the market. Relative to its peer group, NXTC's quantitative score of 28/100 is below the peer average of 76/100.

NXTC Financials

NXTC Latest News

NXTC Analyst Consensus

NXTC MoonshotScore

NextCure, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources